Abbott has earned a CE mark for its quantitative SARS-CoV-2 IgG (immunoglobulin G) blood test, a diagnostic that measures a COVID-19 patient’s level of IgG antibodies.

The European clearance allows the diagnostic to be used on Abbott’s ARCHITECT and Alinity i systems. The company plans to seek an Emergency Use Authorization for the test from the FDA.

The test will help identify “those who are infected as well as determine whether people have had a natural or vaccine-induced immune response,” said John Hackett, divisional vice president of applied research and technology for Abbott’s diagnostics wing. “Quantitative antibody testing can help provide greater understanding of a person’s immune response.”